Publications by authors named "Devis Mmbando"

Claim this Profile
D
Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.
Deborah Watson-Jones, John Changalucha, Caroline Maxwell, Hilary Whitworth, Paul Mutani, Devis Mmbando

Lancet Glob Health· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
Amber Hsiao, Verena Struckmann, Victor Stephani, Devis Mmbando, John Changalucha

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
Deborah Watson-Jones, John Changalucha, Hilary Whitworth, Ligia Pinto, Paul Mutani, Devis Mmbando

Lancet Glob Health· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis